OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Duma on the Importance of Mitigating Racial Disparities in Lung Cancer Research

August 26th 2020

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research.

Dr. Mehta on the Role of Biomarkers in Gastric Cancer

August 26th 2020

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Dr. Trinh on the Challenges of the COVID-19 Pandemic in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer.

Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

August 26th 2020

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

August 26th 2020

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Dr. Ferris on the Safety Profile of Transoral Robotic Surgical Resection in Oropharynx Cancer

August 26th 2020

Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.

Overcoming Racial Inequality in Epithelial Ovarian Cancer Research

August 26th 2020

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm

August 26th 2020

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Dr. Trinh on How COVID-19 Has Impacted Surgical Decisions in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

August 25th 2020

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Dr. Welslau on the Interim Results of the REFLECT Trial in DLBCL

August 25th 2020

Manfred Welslau, MD, discusses the interim results of the REFLECT trial in diffuse large B-cell lymphoma.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

Dr. McGregor on the Evolving Treatment Landscape of RCC

August 25th 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer

August 25th 2020

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

August 24th 2020

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

August 24th 2020

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Dr. Sabari on Novel Immunotherapy Combos Under Investigation in NSCLC

August 24th 2020

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Leslie on Frontline Treatment Options in Follicular Lymphoma

August 24th 2020

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.